Ciraparantag
- Generic Name
- Ciraparantag
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H48N12O2
- CAS Number
- 1438492-26-2
- Unique Ingredient Identifier
- U2R67KV65Q
- Background
Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban).
- Associated Conditions
- -
- Associated Therapies
- -
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-08-12
- Target Recruit Count
- 108
- Registration Number
- NCT04593784
- Locations
- 🇺🇸
Frontage Clinical Services, Secaucus, New Jersey, United States
🇺🇸Qps-Mra, Llc., South Miami, Florida, United States
🇺🇸ICON Early Phase Services, LLC, San Antonio, Texas, United States
Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2020-09-02
- Target Recruit Count
- 60
- Registration Number
- NCT03288454
- Locations
- 🇺🇸
Frontage Clinical Services Inc., Secaucus, New Jersey, United States
Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2020-09-09
- Target Recruit Count
- 69
- Registration Number
- NCT03172910
- Locations
- 🇺🇸
Frontage Clinical Services Inc., Secaucus, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath